全球新城疫疫苗市场规模（依疫苗类型、品种、区域范围和预测）

新城疫疫苗市场规模及预测

2024 年新城疫疫苗市场规模为 2.8927 亿美元，预计到 2032 年将达到 3.7216 亿美元，2026 年至 2032 年的复合年增长率为 3.20%。

新城疫是由禽副黏液病毒1型（APMV-1）引起的一种严重的禽类病毒性疾病。此病传染性极强，可感染多种家禽，包括鸡和火鸡，其中母鸡尤其易感。该病毒透过粪口途径传播，这意味着鸟类可能透过摄入受污染的粪便、食物、饮料或与病禽接触过的设备而感染。

根据美国国家医学图书馆的数据，在2-3週龄时透过气雾剂接种活体新城疫病毒（NDV）活病毒疫苗的商用火鸡，通常不会产生高或持续的血清抗体滴度（血凝抑制试验检测结果）。接种疫苗的火鸡在接种2週后通过眼鼻或气雾剂途径进行攻击时，对感染和临床疾病具有良好的抵抗力，在接种6週后再次攻击时，对临床疾病也具有抵抗力，但保护水平在接种10週后下降。

这些结果表明，可能需要两次或两次以上 NDV 喷雾疫苗接种才能完全保护在 NDV 流行环境中饲养的正在发育的火鸡免受自然 NDV 感染。

禽类严重呼吸窘迫和神经病变率的不断上升，推动了新城疫疫苗市场的大幅扩张。该疾病发病率的不断上升、对食用牲畜的需求的不断增长，以及对该疾病治疗方法的持续研究，预计将推动市场扩张。随着人们越来越意识到保持健康的益处，消费者对优质医疗服务的需求不断增长，新城疫疫苗市场也不断扩大。

新城疫疫苗市场动态

影响全球新城疫疫苗市场的关键市场动态是：

关键市场驱动因素

疾病爆发：鸡新城疫 (ND) 在家禽群体中的存在是新城疫疫苗产业发展的主要动力。随着 ND 持续影响全球家禽养殖场，对有效预防疾病传播的疫苗需求庞大。

家禽业的成长：受全球对肉类和蛋类等家禽产品需求不断增长的推动，家禽业的扩张也推动了新城疫疫苗市场的发展。随着鸡肉产量的增加和向新地区的扩展，对综合疫苗接种计划的需求也日益增长。

环境与生物安全问题：人们对生物安全以及疾病爆发对环境影响的担忧日益加剧，促使人们采取疫苗接种等预防措施。积极主动地预防新城疫，既能保护环境，又能确保养鸡生产系统的长期永续性。

疾病爆发：新城疫疫情导致疫苗接种力道加大，尤其是在家禽产区，并催生了新城疫疫苗的市场需求。疫情爆发会对家禽生产者造成重大经济损失，因此有效疫苗接种工作至关重要。

主要问题

成本限制：新城疫疫苗的高成本阻碍了其推广，尤其是在资源有限的小规模家禽养殖户。开发经济的疫苗配方并采用经济有效的疫苗接种方法，对于该疾病的广泛接受和控制至关重要，尤其是在低收入国家。

生物安全意识不断提升：随着新城疫疫情的爆发日益普遍且大规模，农民逐渐意识到生物安全措施对保护鸡群的重要性。疫苗接种是生物安全措施的关键组成部分，推动了新城疫疫苗的需求。

新株的出现：新城疫病毒不断变异，导致出现新的、更具侵袭性的病毒株。这些新株可能导致现有疫苗失效，因此需要开发新的改良疫苗，而这既耗时又耗资。

疫苗取得管道有限。一些较贫穷的国家取得兽用疫苗（例如新城疫疫苗）的机会有限。这归因于多种因素，包括基础设施不足、资金不足和意识缺乏。这些国家的农民在保护牲畜免受新城疫侵害方面选择较少。

主要趋势

家禽产品需求不断增加：全球人口对鸡肉和鸡蛋的需求不断增长，导致鸡肉产量增加。这导致对疫苗的需求增加，以保护家禽免受新城疫的爆发。新城疫会导致雏鸡死亡并造成巨大的经济损失。

不断加深对新城疫经济影响的认知：家禽生产者越来越意识到新城疫可能造成的经济损失，包括禽类死亡、产蛋量下降以及贸易限制。疫苗接种被认为是预防这些损失的一种经济有效的方式。

疫苗接种技术的进步：正在进行研究和开发，以开发更有效、更耐热的新城疫疫苗，这将有助于疫苗的储存和分发，这在冷藏条件有限的地区尤其重要。

政府立法和疫苗接种计划：许多政府已经采取了针对鸡的新城疫强制疫苗接种计划，以帮助减少疾病的传播，同时保护家禽养殖企业。

目录

第一章 新城疫疫苗全球市场介绍

• 市场概览
• 研究范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

4. 全球新城疫疫苗市场展望

• 概述
• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球新城疫疫苗市场（依疫苗类型）

• 概述
• 活病毒疫苗
• 灭活疫苗

6. 全球新城疫疫苗市场（依品种）

• 概述
• 鸡
• 鸭子和鹅
• 其他的

7. 全球新城疫疫苗市场（按地区）

• 概述
• 北美洲
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 其他亚太地区
• 其他的
  • 拉丁美洲
  • 中东和非洲

8. 全球新城疫疫苗市场竞争格局

• 概述
• 各公司市场排名
• 重点发展策略

第九章 公司简介

• Merck Animal Health
• GALVmed
• Elanco
• Boehringer Ingelheim
• QYH BIoTech
• Ceva Animal Health LLC
• Hester Biosciences Limited
• Zoetis, Inc.
• CAVAC

第十章 附录

• 相关调查

Newcastle Disease Vaccine Market Size And Forecast

Newcastle Disease Vaccine Market size was valued at USD 289.27 Million in 2024 and is projected to reach USD 372.16 Million by 2032, growing at a CAGR of 3.20% from 2026 to 2032.

Newcastle disease is a severe viral sickness in birds caused by avian paramyxovirus type 1 (APMV-1). It is very contagious and can spread too many domestic birds, including chickens and turkeys, with hens being especially vulnerable. The virus is spread by the fecal-oral route, which means that birds become infected after consuming contaminated droppings, food, drink, or equipment that has come into contact with sick birds.

According to National Library of Medicine, Commercial market turkeys spray-vaccinated at 2 to 3 weeks of age with live Newcastle disease virus (NDV) vaccine did not often generate high or persistent serum antibody levels as detected by the hemagglutination-inhibition test. Vaccinated turkeys demonstrated adequate resistance to infection and clinical disease when challenged by the oculonasal or aerosol route at 2 weeks post-vaccination, and they resisted clinical disease when challenged at 6 weeks, but the level of protection decreased by 10 weeks post-vaccination.

It is proposed that market turkeys raised in an NDV-enzootic environment may require two or more NDV spray vaccinations during their developing phase in order to be fully protected against natural NDV infection.

The increasing incidence of severe respiratory distress and nervous difficulties in birds contributes to the huge expansion of the Newcastle Disease Vaccine Market. Expanding outbreaks of the disease, expanding demand for livestock for food, and continuous research to produce a treatment for this disease are expected to drive market expansion. The Newcastle Disease Vaccine Market is thriving as people become more aware of the benefits of maintaining good health, resulting in a greater demand for high-quality healthcare services among consumers.

Newcastle Disease Vaccine Market Dynamics

The key market dynamics that are shaping the global Newcastle disease vaccine market include:

Key Market Drivers:

Disease Prevalence: The presence of Newcastle disease (ND) in poultry populations is a major driver of the Newcastle disease vaccine industry. As ND continues to affect poultry farms around the world, there is a great demand for effective vaccines to prevent the disease from spreading.

Growth of the Poultry Industry: The expansion of the poultry industry, fueled by rising global demand for chicken products such as meat and eggs, helps to drive the Newcastle disease vaccine market. As chicken production increases and spreads into new areas, the necessity for comprehensive immunization programs becomes increasingly pressing.

Environmental and Biosecurity Concerns: Growing concern about biosecurity and the environmental impact of disease outbreaks is driving the use of preventive measures like immunization. Proactive steps to avoid Newcastle disease can save the environment while also ensuring the long-term viability of chicken production systems.

Disease Outbreaks: Newcastle disease outbreaks, particularly in poultry-producing regions, lead to intensified immunization efforts and generate market demand for Newcastle disease vaccines. Outbreaks can cause large economic losses for poultry producers, highlighting the significance of effective vaccination efforts.

Key Challenges:

Cost Constraints: The high cost of Newcastle disease vaccines can deter adoption, especially among small-scale chicken breeders with limited financial resources. Developing economical vaccine formulations and adopting cost-effective immunization procedures is critical for ensuring widespread acceptance and disease control particularly in low-income nations.

Increased Biosecurity Awareness: As Newcastle disease outbreaks become more common and extensive, farmers recognize the significance of biosecurity measures to protect their flocks. Vaccination is a critical component of biosecurity measures, which is boosting the demand for Newcastle disease vaccine.

Emergence of New Strains: The Newcastle disease virus is constantly mutating, with new and more aggressive strains appearing. These novel strains may render current vaccines ineffective, prompting the creation of new and improved vaccines. This can be a long and costly process.

Limited Access to Vaccines: Some impoverished countries have limited access to veterinary vaccines, such as Newcastle disease vaccines. This is due to a variety of issues, including inadequate infrastructure, money, and awareness. Farmers in these nations have fewer options for protecting their animals from Newcastle disease.

Key Trends:

Rising Demand for Chicken Products: The global population's expanding appetite for poultry meat and eggs has resulted in increased poultry production. This increases the need for immunization to protect birds from Newcastle disease outbreaks, which may kill chicks and result in considerable economic losses.

Increasing Knowledge of Newcastle Disease's Economic Impact: Poultry growers are becoming more conscious of the financial losses caused by Newcastle disease. This includes avian mortality, reduced egg output, and trade restrictions. Vaccination is viewed as a cost-effective method of preventing these losses.

Advances in Vaccination Technology: Research and development are underway to build more effective and thermostable Newcastle disease vaccines. This is especially significant in areas with limited refrigeration access, as it facilitates vaccine storage and distribution.

Government Laws and Immunization Programs: Many governments have adopted mandatory vaccination programs against Newcastle disease in chicken. This helps to control disease spread while also protecting the poultry business.

Global Newcastle Disease Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the global Newcastle disease vaccine market:

North America:

The Newcastle disease vaccine market, owing to a robust chicken sector and high demand for poultry products, including meat and eggs. The region's chicken industry is well-established, but Newcastle disease poses ongoing challenges needing stringent preventive measures such as immunization. This need emphasizes the importance of Newcastle disease vaccines in protecting the region's poultry stock and assuring the continuation of its thriving poultry market.

Furthermore, North America's unwavering dedication to sustainable agriculture techniques and animal welfare encourages the use of Newcastle disease vaccines. Prioritizing poultry health and well-being demonstrates the region's commitment to sustaining high food safety and animal care standards, which resonates positively with both consumers and industry stakeholders.

North America's dominant market position not only represents its enormous contribution to the global Newcastle disease vaccine market, but also demonstrates its unwavering commitment to safeguarding the poultry industry's viability and resilience in the face of evolving disease threats.

Asia Pacific:

The Asia-Pacific region is expected to lead the Newcastle disease vaccine market, as it is home to some of the world's top poultry producers, including China, India, and Indonesia. Here, rising demand for poultry products, fueled by population growth and changing dietary habits, drives the need to protect poultry flocks from Newcastle disease outbreaks. As a result, there is a significant increase in demand for vaccines, emphasizing the importance of preventive measures in supporting the region's thriving poultry sector.

Furthermore, the Asia-Pacific area is experiencing tremendous development in the poultry business, as well as increased knowledge of biosecurity regulations. This double momentum not only strengthens the Newcastle disease vaccine market but also demonstrates the region's proactive approach to disease prevention in chicken production. These factors firmly position Asia-Pacific as a key catalyst for Newcastle disease vaccine market growth, demonstrating its critical role in maintaining the global poultry industry's resilience in the face of changing challenges.

Europe:

The European market is primed to emerge as a serious competitor, boosted by proactive government programs that assist research and development efforts, particularly in the field of Newcastle disease vaccines. With significant investments in improving veterinary science and tight regulatory frameworks, the region creates an atmosphere conducive to innovation in animal health solutions.

Furthermore, Europe's significant advancements in animal husbandry procedures strengthen its position in the Newcastle disease vaccine market. By embracing innovative techniques and technology aimed at improving animal welfare and disease prevention, the region demonstrates its commitment to upholding high animal health and food safety standards. This combination of government funding, scientific excellence, and modern husbandry techniques puts Europe as a major player set to make great advances in the international Newcastle disease vaccine market.

Global Newcastle Disease Vaccine Market: Segmentation Analysis

The Global Newcastle Disease Vaccine Market is segmented on the basis of Vaccine Type, Species, And Geography.

Newcastle Disease Vaccine Market, By Vaccine Type

• Live Attenuated
• Inactivated
• Thermostable

Based on Vaccine Type, the market is divided into Live Attenuated, Inactivated and Thermostable. The Live Attenuated Vaccines (LAV) segment dominated the market in 2022 and is expected to have the highest compound annual growth rate (CAGR) over the forecast period. LAVs have remained popular among poultry breeders due to their effectiveness, low cost, and potential to provide long-term immunity. These vaccines have demonstrated efficacy against many strains of Newcastle disease viruses and provide broad-spectrum protection.

Newcastle Disease Vaccine Market, By Species

• Chicken
• Duck
• Goose

Based on Species, the Newcastle disease vaccine market is segmented Chicken, Duck and Goose. The chicken sector grabbed the biggest market share and is expected to retain a significant compound annual growth rate (CAGR) over the projection period. Newcastle Disease Virus (NDV) is a major threat to the poultry industry, causing significant economic losses. As a result, the demand for Newcastle Disease Vaccines remains high among chicken farmers, making this segment the most profitable in the market.

Newcastle Disease Vaccine Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of regional analysis, the Global Newcastle Disease Vaccine Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America accounted for the largest market share of Newcastle disease vaccine followed by Europe. Growing demand for effective emergency care and increasing adoption of mobile surgery centers are anticipated to drive the industry during the forecast period.

Key Players

The "Global Newcastle disease vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Merial, QYH Biotech, CEVA, Yebio, Ringpu (Tianjin) Bio-Pharmacy Co. Ltd,Bayer AG, Hipra, Anicon Labor GmbH, Chengdu Tech-bank Biological Products Co. Ltd., Ringpu Bio-Technology Co. Ltd., MSD Animal Health, Nisseiken Co., Harbin Veterinary Research Institute, Merck Animal Health, ChengDu Tecbond, DHN, Zoetis, Elanco (Lohmann), CAVAC, Vaksindo, FATRO. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Newcastle Disease Vaccine Market Recent Developments
• In June 2022, Ceva Sante bought Canadian firm Artemis Technologies, Inc. to extend its oral rabies vaccine line. Ceva's North American presence will be expanded as a result of this transaction.
• In April 2020, The Indian Institute of Technology Guwahati and Hester Biosciences cooperated to create a new coronavirus vaccine (COVID-19). The vaccine is based on a recombinant avian paramyxovirus vector platform.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NEWCASTLE DISEASE VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NEWCASTLE DISEASE VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY VACCINE TYPE

• 5.1 Overview
• 5.2 Live vaccines
• 5.3 Killed vaccines

6 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY SPECIES

• 6.1 Overview
• 6.2 Chicken
• 6.3 Duck and goose
• 6.4 Others

7 GLOBAL NEWCASTLE DISEASE VACCINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Rest of the World
  • 7.5.1 Latin America
  • 7.5.2 Middle East and Africa

8 GLOBAL NEWCASTLE DISEASE VACCINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies

9 COMPANY PROFILES

• 9.1 Merck Animal Health
  • 9.1.1 Overview
  • 9.1.2 Financial Performance
  • 9.1.3 Product Outlook
  • 9.1.4 Key Developments
• 9.2 GALVmed
  • 9.2.1 Overview
  • 9.2.2 Financial Performance
  • 9.2.3 Product Outlook
  • 9.2.4 Key Developments
• 9.3 Elanco
  • 9.3.1 Overview
  • 9.3.2 Financial Performance
  • 9.3.3 Product Outlook
  • 9.3.4 Key Developments
• 9.4 Boehringer Ingelheim
  • 9.4.1 Overview
  • 9.4.2 Financial Performance
  • 9.4.3 Product Outlook
  • 9.4.4 Key Developments
• 9.5 QYH Biotech
  • 9.5.1 Overview
  • 9.5.2 Financial Performance
  • 9.5.3 Product Outlook
  • 9.5.4 Key Developments
• 9.6 Ceva Animal Health LLC
  • 9.6.1 Overview
  • 9.6.2 Financial Performance
  • 9.6.3 Product Outlook
  • 9.6.4 Key Developments
• 9.7 Hester Biosciences Limited
  • 9.7.1 Overview
  • 9.7.2 Financial Performance
  • 9.7.3 Product Outlook
  • 9.7.4 Key Developments
• 9.8 Zoetis, Inc.
  • 9.8.1 Overview
  • 9.8.2 Financial Performance
  • 9.8.3 Product Outlook
  • 9.8.4 Key Developments
• 9.9 CAVAC
  • 9.9.1 Overview
  • 9.9.2 Financial Performance
  • 9.9.3 Product Outlook
  • 9.9.4 Key Developments

10 Appendix

• 10.1 Related Research